Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

AGM Statement

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement the business now has a clear strategic focus and we have in place a commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales.

We have had a positive start to trading in the first quarter of the new financial year and remain confident that we will return the business to growth in 2014.

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.